Since the introduction of SMN2-modifying therapies such as nusinersen and risdiplam, the great importance of SMN2 copy numbers has been widely realized and tested in suspected SMA patients recently in China. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.